Effects of a probiotic suspension Symprove™ on a rat early-stage Parkinson’s disease model
An increasing number of studies in recent years have focused on the role that the gut may play in Parkinson’s Disease (PD) pathogenesis, suggesting that the maintenance of a healthy gut may lead to potential treatments of the disease. The health of microbiota has been shown to be directly associated...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2023-01-01
|
| Series: | Frontiers in Aging Neuroscience |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fnagi.2022.986127/full |
| _version_ | 1828061615971368960 |
|---|---|
| author | Marco Sancandi Carmen De Caro Neringa Cypaite Nadia Marascio Carmen Avagliano Carmela De Marco Emilio Russo Andrew Constanti Audrey Mercer |
| author_facet | Marco Sancandi Carmen De Caro Neringa Cypaite Nadia Marascio Carmen Avagliano Carmela De Marco Emilio Russo Andrew Constanti Audrey Mercer |
| author_sort | Marco Sancandi |
| collection | DOAJ |
| description | An increasing number of studies in recent years have focused on the role that the gut may play in Parkinson’s Disease (PD) pathogenesis, suggesting that the maintenance of a healthy gut may lead to potential treatments of the disease. The health of microbiota has been shown to be directly associated with parameters that play a potential role in PD including gut barrier integrity, immunity, function, metabolism and the correct functioning of the gut-brain axis. The gut microbiota (GM) may therefore be employed as valuable indicators for early diagnosis of PD and potential targets for preventing or treating PD symptoms. Preserving the gut homeostasis using probiotics may therefore lead to a promising treatment strategy due to their known benefits in improving constipation, motor impairments, inflammation, and neurodegeneration. However, the mechanisms underlying the effects of probiotics in PD are yet to be clarified. In this project, we have tested the efficacy of an oral probiotic suspension, Symprove™, on an established animal model of PD. Symprove™, unlike many commercially available probiotics, has been shown to be resistant to gastric acidity, improve symptoms in gastrointestinal diseases and improve gut integrity in an in vitro PD model. In this study, we used an early-stage PD rat model to determine the effect of Symprove™ on neurodegeneration and neuroinflammation in the brain and on plasma cytokine levels, GM composition and short chain fatty acid (SCFA) release. Symprove™ was shown to significantly influence both the gut and brain of the PD model. It preserved the gut integrity in the PD model, reduced plasma inflammatory markers and changed microbiota composition. The treatment also prevented the reduction in SCFAs and striatal inflammation and prevented tyrosine hydroxylase (TH)-positive cell loss by 17% compared to that observed in animals treated with placebo. We conclude that Symprove™ treatment may have a positive influence on the symptomology of early-stage PD with obvious implications for the improvement of gut integrity and possibly delaying/preventing the onset of neuroinflammation and neurodegeneration in human PD patients. |
| first_indexed | 2024-04-10T22:16:39Z |
| format | Article |
| id | doaj.art-a406997869b24052b72c205c2a1b8c38 |
| institution | Directory Open Access Journal |
| issn | 1663-4365 |
| language | English |
| last_indexed | 2024-04-10T22:16:39Z |
| publishDate | 2023-01-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Aging Neuroscience |
| spelling | doaj.art-a406997869b24052b72c205c2a1b8c382023-01-18T07:45:22ZengFrontiers Media S.A.Frontiers in Aging Neuroscience1663-43652023-01-011410.3389/fnagi.2022.986127986127Effects of a probiotic suspension Symprove™ on a rat early-stage Parkinson’s disease modelMarco Sancandi0Carmen De Caro1Neringa Cypaite2Nadia Marascio3Carmen Avagliano4Carmela De Marco5Emilio Russo6Andrew Constanti7Audrey Mercer8Department of Pharmacology, UCL School of Pharmacy, London, United KingdomDepartment of Science of Health, School of Medicine, University of Catanzaro, Catanzaro, ItalyDepartment of Pharmacology, UCL School of Pharmacy, London, United KingdomDepartment of Science of Health, School of Medicine, University of Catanzaro, Catanzaro, ItalyDepartment of Pharmacy, University of Naples Federico II, Napoli, ItalyDepartment of Experimental and Clinical Medicine, Magna Græcia University of Catanzaro, Catanzaro, ItalyDepartment of Science of Health, School of Medicine, University of Catanzaro, Catanzaro, ItalyDepartment of Pharmacology, UCL School of Pharmacy, London, United KingdomDepartment of Pharmacology, UCL School of Pharmacy, London, United KingdomAn increasing number of studies in recent years have focused on the role that the gut may play in Parkinson’s Disease (PD) pathogenesis, suggesting that the maintenance of a healthy gut may lead to potential treatments of the disease. The health of microbiota has been shown to be directly associated with parameters that play a potential role in PD including gut barrier integrity, immunity, function, metabolism and the correct functioning of the gut-brain axis. The gut microbiota (GM) may therefore be employed as valuable indicators for early diagnosis of PD and potential targets for preventing or treating PD symptoms. Preserving the gut homeostasis using probiotics may therefore lead to a promising treatment strategy due to their known benefits in improving constipation, motor impairments, inflammation, and neurodegeneration. However, the mechanisms underlying the effects of probiotics in PD are yet to be clarified. In this project, we have tested the efficacy of an oral probiotic suspension, Symprove™, on an established animal model of PD. Symprove™, unlike many commercially available probiotics, has been shown to be resistant to gastric acidity, improve symptoms in gastrointestinal diseases and improve gut integrity in an in vitro PD model. In this study, we used an early-stage PD rat model to determine the effect of Symprove™ on neurodegeneration and neuroinflammation in the brain and on plasma cytokine levels, GM composition and short chain fatty acid (SCFA) release. Symprove™ was shown to significantly influence both the gut and brain of the PD model. It preserved the gut integrity in the PD model, reduced plasma inflammatory markers and changed microbiota composition. The treatment also prevented the reduction in SCFAs and striatal inflammation and prevented tyrosine hydroxylase (TH)-positive cell loss by 17% compared to that observed in animals treated with placebo. We conclude that Symprove™ treatment may have a positive influence on the symptomology of early-stage PD with obvious implications for the improvement of gut integrity and possibly delaying/preventing the onset of neuroinflammation and neurodegeneration in human PD patients.https://www.frontiersin.org/articles/10.3389/fnagi.2022.986127/fullSymprove probioticsgut integrityshort chain fatty acidsParkinson’s diseaserat model |
| spellingShingle | Marco Sancandi Carmen De Caro Neringa Cypaite Nadia Marascio Carmen Avagliano Carmela De Marco Emilio Russo Andrew Constanti Audrey Mercer Effects of a probiotic suspension Symprove™ on a rat early-stage Parkinson’s disease model Frontiers in Aging Neuroscience Symprove probiotics gut integrity short chain fatty acids Parkinson’s disease rat model |
| title | Effects of a probiotic suspension Symprove™ on a rat early-stage Parkinson’s disease model |
| title_full | Effects of a probiotic suspension Symprove™ on a rat early-stage Parkinson’s disease model |
| title_fullStr | Effects of a probiotic suspension Symprove™ on a rat early-stage Parkinson’s disease model |
| title_full_unstemmed | Effects of a probiotic suspension Symprove™ on a rat early-stage Parkinson’s disease model |
| title_short | Effects of a probiotic suspension Symprove™ on a rat early-stage Parkinson’s disease model |
| title_sort | effects of a probiotic suspension symprove™ on a rat early stage parkinson s disease model |
| topic | Symprove probiotics gut integrity short chain fatty acids Parkinson’s disease rat model |
| url | https://www.frontiersin.org/articles/10.3389/fnagi.2022.986127/full |
| work_keys_str_mv | AT marcosancandi effectsofaprobioticsuspensionsymproveonaratearlystageparkinsonsdiseasemodel AT carmendecaro effectsofaprobioticsuspensionsymproveonaratearlystageparkinsonsdiseasemodel AT neringacypaite effectsofaprobioticsuspensionsymproveonaratearlystageparkinsonsdiseasemodel AT nadiamarascio effectsofaprobioticsuspensionsymproveonaratearlystageparkinsonsdiseasemodel AT carmenavagliano effectsofaprobioticsuspensionsymproveonaratearlystageparkinsonsdiseasemodel AT carmelademarco effectsofaprobioticsuspensionsymproveonaratearlystageparkinsonsdiseasemodel AT emiliorusso effectsofaprobioticsuspensionsymproveonaratearlystageparkinsonsdiseasemodel AT andrewconstanti effectsofaprobioticsuspensionsymproveonaratearlystageparkinsonsdiseasemodel AT audreymercer effectsofaprobioticsuspensionsymproveonaratearlystageparkinsonsdiseasemodel |